This is a routine post-annual-meeting filing with no earnings or operational data. The authorized share increase and equity plan approvals signal potential future dilution for equity grants or capital raises, but no immediate catalyst. Monitor for subsequent equity issuances or grant activity under the new plans.
PALI drugs
PALI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $1.71entry
- T+1 · 5mo ago −1.17%α −2.93% · $1.69
- T+5 · 5mo ago +9.36%α +8.68% · $1.87
- T+20 · 4mo ago +14.62%α +12.84% · $1.96
- T+60 · 2mo ago +28.66%α +25.39% · $2.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palisade Bio filed an 8-K reporting its 2026 annual meeting results, including stockholder approval to increase authorized common shares from 300M to 450M, adoption of an amended equity incentive plan (42.257M shares reserved) and ESPP (837K shares reserved), and the appointment of Jordan Zwick to the board with a $566,000 RSU grant. These are routine governance and capital-structure actions that provide headroom for future equity grants but do not reflect any change in operating performance or business outlook.
Key Facts
- Authorized common shares increased from 300,000,000 to 450,000,000, effective June 11, 2026.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, reserving 42,257,000 shares for future awards.
- Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan, reserving 837,000 shares.
- Board expanded from five to six directors; Jordan Zwick appointed as independent director and Audit Committee member.
- Mr. Zwick receives an initial RSU grant valued at $566,000, vesting in three equal annual installments.
- All four incumbent directors (J.D. Finley, Donald Williams, Emil Chuang, Robert F. Baltera, Jr.) were re-elected.
- Baker Tilly US, LLP ratified as independent auditor for FY2026.
- Non-binding advisory vote on executive compensation passed with 58% of votes cast in favor.
- Equity grants to non-employee directors approved by stockholders.
Financial Impact
No immediate financial impact. The authorized share increase and equity plan amendments provide capacity for future equity compensation and potential capital raises, but no issuance has occurred.
Risk Factors
- Potential future dilution from up to 42.257M new shares under the equity incentive plan and 837K under the ESPP.
- No financial results or guidance provided in this filing, business performance unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028322 |
| Exhibit: ex10-3.htm | 0001493152-26-028322 |
| Exhibit: ex3-1.htm | 0001493152-26-028322 |
| Document: form8-k.htm | 0001493152-26-028322 |
| Document: 0001493152-26-028322-index-headers.html | 0001493152-26-028322 |
| Document: 0001493152-26-028322-index.html | 0001493152-26-028322 |
| Document: 0001493152-26-028322.txt | 0001493152-26-028322 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Viewing Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers